Skip to content

From Psoriasis to Arthritis

A systems biology approach to identify novel biomarkers and causative pathways in patients with psoriatic arthritis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON29587
Enrollment
900
Registered
2014-06-03
Start date
2014-07-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psoriasis

Interventions

Sponsors

UMC Utrecht
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - The patient is age 18 - 75 years of age. - For Population 1: a diagnosis of psoriasis made by a dermatologist - For Population 2: a diagnosis of PsA according to CASPAR criteria and not yet treated with DMARDs or Biologicals - For Population 3: a diagnosis of PsA according to CASPAR criteria and treated with DMARDs and/or Biologicals - For Population 4: a diagnosis of SpA made by a rheumatologist, where the SpA is caused by an alternative disease than PsA, namely: ankylosing spondylitis (AS), inflammatory bowel disease associated arthritis, reactive arthritis, or undifferentiated spondyloarthritis.

Exclusion criteria

Exclusion criteria: - The patient is age 17 years or younger - The patient is age 76 years or older - The patient has an alternative inflammatory rheumatological diagnosis (e.g. RA, gout, pseudo-gout). - For Population 2: past or current treatment with DMARDs or Biologicals.

Design outcomes

Primary

MeasureTime frame
- diagnose (artritis psoriatica versus psoriasis)

Secondary

MeasureTime frame
- ziekteactiviteit

Contacts

Public ContactE.F.A. Leijten

Laboratory Translational Immunology, Department of Rheumatology & Clinical Immunology University Medical Centre Utrecht P.O.Box 85090

eleijte2@umcutrecht.nl+31 (0)887553215

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)